Augmenix Secures $3,000,000 New Financing

  • Feed Type
  • Date
    1/3/2011
  • Company Name
    Augmenix
  • Mailing Address
    204 2nd Avenue Waltham, MA 02451
  • Company Description
    Augmenix, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers.
  • Website
    http://www.augmenix.com
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
    $3,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.